MET Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
MetLife Inc (MET) is not a strong buy for a beginner investor with a long-term focus at this moment. While the stock has potential for moderate growth in the next month, the lack of significant positive catalysts, declining financial performance, and hedge fund selling trends suggest holding off on investment until clearer signals of strength emerge.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 49.199, showing no clear overbought or oversold conditions. Moving averages are converging, and the stock is trading near its S1 support level of 75.452, which could act as a potential floor. The pre-market price of 75.53 is down 2.37%, reflecting bearish sentiment.
No significant positive catalysts identified. Analysts have maintained some Buy ratings, and the stock has potential for moderate growth in the next month.
Hedge funds are selling heavily, with a 119940.49% increase in selling activity. Financial performance in Q4 2025 showed a significant decline in Net Income (-37.21% YoY) and EPS (-34.27% YoY). Analysts have lowered price targets, and there is no recent positive news or congress trading data to support the stock.
In Q4 2025, revenue increased by 27.44% YoY to $23.81 billion, but Net Income dropped by 37.21% YoY to $778 million, and EPS fell by 34.27% YoY to 1.17. This indicates revenue growth but declining profitability.
Analysts have mixed ratings. UBS and BofA maintain Buy ratings with price targets of $98, while Evercore ISI and Barclays have downgraded the stock or lowered price targets. Concerns include commercial mortgage loan risks, low new-money spreads, and potential downside to forward earnings.
